Hemostatic Derangements in Patients with Solid Malignant Tumors

Mazin R. Mohammed; Saad S. Mansoor; Mustafa Ghany Taher

Author(s)

Mazin R. Mohammed Baqubah teaching hospital,Diyala,Iraq

Saad S. Mansoor Baqubah teaching hospital,Diyala,Iraq

Mustafa Ghany Taher Assistant Lecturer, Department of Pathology, College of Medicine Diyala University,Diyala,Iraq

Abstract

BACKGROUND: Cancer patients show an increased susceptibility to thromboembolic diseases. Although clinical symptoms occur less frequently, disorders of coagulation are very common in cancer patients. The aim of the study was to determine the presence of hemostatic derangements in patients suffering from solid malignant tumors. METHODS: This case-controlled study was conducted on patients with solid malignant tumors who presented to Al-Yermok Teaching Hospital and Hospital of Radiation and Nuclear Medicine in Iraq, from January 2004 to July 2004. Forty cases were included in the study and the control group included fifteen age and gender matched healthy volunteers. Platelet count was determined from blood sample, while tests for prothrombin time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), fibrinogen and D-dimer were conducted on plasma. RESULTS: Fourteen patients had slight concurrent bleeding; only one patient gave history of recurrent attacks of deep venous thrombosis. The most common hemostatic abnormalities were elevated D-dimer (45%, n=18), thrombocytosis (27.5%, n=11), prolonged TT (25%, n=10) and hyperfibrinogenemia (25%, n=10). The mean PT, aPTT and TT were higher in subjects with malignancies as compared to the healthy controls; and these variables were also higher in those with evidence of intravascular coagulation and fibrinolysis (ICF) as compared to those without ICF syndrome. The mean fibrinogen level and platelet count were higher in patients with malignancy (mean=3.1 g/L) and (mean=317.8 x 109/L) as compared to healthy controls (mean=3 g/L and mean=260.7 x 109/L) respectively where the (p=0.02 and p=0.08) respectively; moreover, the mean of platelets tended to be lower when there was evidence of decompensated type ICF (mean=125 x 109/L), rather than compensated type (mean=171.4 x 109/L) or over compensated type (mean=491.4 x 109/L). The rate of occurrence of ICF syndrome was not significantly higher with adenocarcinoma than that with other histologic types (p=0.18). On the other hand, this rate was significantly higher with high grade tumor than with low grade tumor and in patients with distant metastasis (p=0.001). CONCLUSION: Hemostatic derangement is common in patients with a wide variety of malignancies. The plasma D-dimer test with other indices of DIC syndrome forms a good and simple applicable panel of tests for assessment of ICF syndrome.

Publication Details

Page(s) 1-9

DOI DOI not available

Published Journal: Journal of Pioneering Medical Sciences, Volume: 3, Issue: 1, Year: 2013

Request the full text from PASTIC

Keywords

Hemostatic derangement, D-dimer, Solid malignant tumor

References

Loreto MF,Martinis MD,Corsi MP,Modesti M .2000 .Coagulation and cancer. Pathology Oncology Research, 6 : 302-312.

Soong BCF,Miller SO .1970 .Coagulation disorders in cancer, III fibrinolysis and inhibitor. Cancer, 25 : 867-873.

Ambrus JL,Ambrus CM,Mink IB,pickren JW .1975 .Causes of death in cancer patients. J Med, 6 : 61-64.

Hagedorn AB,Bowie Ejw,Elveback LR,Owen CA .1974 .Coagulation abnormalities in patients with inoperable lung cancer. Mayo Cli Proc, 49 : 649-653.

Sun NC,MCAfee WM,Hum GJ,Weiner JM .1979 .Haemostatic abnormalities in malignancy: A prospective study in one hundred eight patients, part 1. Am J Clin Path, 71 : 10-16.

Gordon SG,crosses BA .1981 .Factor X- activity cystic protease from malignant tissue. J Clin Invest, 67 : 1665-1671.

Hagedorn AB,Bowie Ejw,Elveback LR,Owen CA .1974 .Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc, 49 : 649-653.

Sun NC,MCAfee WM,Hum GJ,Weiner JM .1979 .Haemostatic abnormalities in malignancy: A prospective study In one hundred eight patient, parts 1. Am J Clin Path, 71 : 10-16.

Seligsohn URI,Lichtman MA .1995 .Disseminated intravascular. MC Graw - Hill publishing company, USA, : 1497-1516.

Greenberg CS,Devine DV,McCrae KM .1987 .Measurment of plasma D- dimer levels with the use of a monoclonal antibody coupled to latex beads. Am J Cli Pathol, 1 : 94-100.

Taylor FB,Toh CH,Hoots WK,Wada H,Levi M .2001 .Definition and scoring system for Disseminated Intravascular coagulation. Thromb Haemost, 86 : 1327-1330.

Okajima K,Sakamoto Y,Uchiba M .2000 .Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: Study of 204 cases. Am J Haematol, 65 : 215-222.

Maegawa T,Takada M,Tanaka H,Gonmoie H .1987 .Criteria for diagnosis of DIC based on the analysis of clinical and laboratory finding in 345 DIC patients collected by the research committee on DIC in Japan. Bibl Haematol, 49 : 265-275.

Goldsmith GH .2001 .Haemostatic changes in patients with malignancy. Int J Haematol, 73(2) : 151-156.

Frederick R,Richard L .1983 .Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood, 62 : 14-31.

Wilde JT .1989 .Plasma D - dimer levels and their relationship to serum fibrinogen \ fibrin degradation products in hypercoagulable state. Br J Haematol, 71 : 65-70.

Levin J,Conely cL .1964 .Thrombocytosis associated with malignant disease. Arch Inter Med, 114 : 497-500.

Davis RB,Theologies A,Kennedy BJ .1969 .Comparative studies of blood coagulation and platelet aggregation in patients with cancer and non - malignant disease. Ann Int Med, 71 : 67-80.

Saikh BS,Bullard V .1977 .Thrombopoietic activity from sera of cancer patients. Blood, 50(suppl 1) : 252.

Zakim D,Boyer D Thomas: Hepatology Test Book Of Liver Disease D .2001 .. , : 550-580.

Andrew F,Huatiuk W,Circulating D - .2002 .dimer in patients with sarcoidosis. Chest, 117 : 1012-1016.

Elms MJ,Bundesen PG,Rylatt DS .1986 .Rapid detection of cross-linked fibrin degradation products in plasma using monoclonal antibody coated latex particles. Am J Clin Pathol, 3 : 360-364.

Elms MJ,Bunce IH,Bundesen PG .1983 .Measurement of cross linked fibrin degradation products an immunoassay using a monoclonal antibodies. Thromb Haemost, 50 : 591-594.

Trofatter KF,Howell ML,Greeb ML .1989 .Use of the fibrin D- dimer in screening for coagulation abnormalities in preeclampsia. Obstet Gynecol, 3 : 435-439.

Hajjar KA,Esmon NL,Marcus AJ,Lightman MA,Culler BS,Kipps TJ .2001 .Vascular function in. Williams Haematology 6th ed, New York. Mc GrawHill Company, 114 : 1451-1469.

Kin HK,song KS,Kyung Sb,Lee KR,kany YH,Lee YH,Lee ES .2004 .Comparison of plasma D - dimer and thrombus precursor protein in patients with operable breast cancer as a potential predictor of lymph node metastasis. Blood Coagulation and Fibrinolysis, 15 : 1-13.

Frederick R,Richard L .1983 .Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood, 62 : 14-31.